Antidote to Factor Xa Inhibitors Shows Promise

ESC 2011 — PARIS — Oral direct factor Xa inhibitors are an emerging class of drugs that are poised take much of the market from warfarin on a wave of enthusiasm about their ease of use and reported safety, but, amid the hype, one fact remains: drugs like rivaroxaban (Xarelto) and apixaban (Eliquis) don't have an antidote.

Keywords: ESC Congress

< Back to Listings